Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01130688 · ClinicalTrials.gov registry record · Phase 1
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
A Phase 1 study, sponsored by University of Massachusetts, Worcester.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01130688 is a Phase 1 study that was terminated before completion, run by University of Massachusetts, Worcester. The registered enrollment target is 2 participants.
The verdict
NCT01130688, a Phase 1 study, was terminated before completion, sponsored by University of Massachusetts, Worcester.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The leukemic stem cells (LSCs) are cells that self- renew and give rise to leukemia. Eradication of LSC is required for cure. In chronic myelogenous leukemia (CML) LSCs are not eradicated by imatinib (Gleevec) alone. Recent discovery by Dr. Shaoguang Li at University of Massachusetts indicates that the LSCs can be targeted by a new drug zileuton (Chen et al. Nature Genetics 2009; 41:783-792). Zileuton (approved for asthma) will be tested in a combination with Gleevec. This combination has not been used previously to treat leukemia. This is a Phase I study. The goal of this research is to evaluate the safety of the standard anti-cancer drug imatinib and experimental drug zileuton.
Interventions
- DRUG Zileuton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01130688
The ClinicalTrials.gov registry entry for NCT01130688 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zileuton is the first listed.
NCT01130688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01130688 about?
NCT01130688 is a clinical study titled "Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.". The leukemic stem cells (LSCs) are cells that self- renew and give rise to leukemia. Eradication of LSC is required for cure. In chronic myelogenous leukemia (CML) LSCs are not eradicated by imatinib (Gleevec) alone. Recent discovery by Dr. Shaoguang Li at University of Massachusetts indicates that ...
What is the current status of trial NCT01130688?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2010-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01130688?
The interventions under investigation include: Zileuton (DRUG).
Who is sponsoring clinical trial NCT01130688?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.